Claris Lifesciences announced that it has received the Abbreviated New Drug Application (ANDA) approval for Furosemide Injection in the United States of America (US). This product will be sold in 10mg/ml formulation packed in 20mg/2ml, 40mg/4ml and 100mg/10ml single dose vials having approx market size of USD 22 million.

This brings Claris' total tally of approved and marketable ANDAs to 13 with estimated addressable market size of USD 204.33 million.

Furosemide is used to treat edema (fluid retention) that occurs with congestive heart failure and disorders of the liver, kidney and lung. It is also used to control mild to moderate high blood pressure. It may be used in combination with other medications to treat more severe high blood pressure.

The product has been facing supply issues in the US during the past year on various occasions and has also featured in the USFDA shortage list since June 2012.

Shares of the company declined Rs 0.95, or 0.53%, to settle at Rs 177.65. The total volume of shares traded was 26,956 at the BSE (Thursday).